1076 related articles for article (PubMed ID: 26865511)
1. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
2. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
3. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
6. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
[TBL] [Abstract][Full Text] [Related]
8. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
12. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
19. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
[TBL] [Abstract][Full Text] [Related]
20. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
